预约演示
更新于：2025-05-24
Ciclesonide
环索奈德
更新于：2025-05-24
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (2004-02-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS号126544-47-6 |
关联
108
项与 环索奈德 相关的临床试验CTR20244577
环索奈德吸入气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
CTR20233942
环索奈德气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
EUCTR2020-002208-37-DK
The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare utilization, disease progression and symptoms in the treatment of mild-to-moderate COVID-19. - CIMMCov
100 项与 环索奈德 相关的临床结果
登录后查看更多信息
100 项与 环索奈德 相关的转化医学
登录后查看更多信息
100 项与 环索奈德 相关的专利（医药）
登录后查看更多信息
758
项与 环索奈德 相关的文献（医药）2025-06-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Formulation of a dry powder for inhalation combining ciclesonide and indacaterol maleate using spray drying
Article
作者: Coeurderoi, Alice ; Evrard, Brigitte ; Sacré, Pierre-Yves ; Piel, Géraldine ; Cataldo, Didier ; Bya, Laure-Anne ; Bottero, Benedetta ; Dinh, Tuan Nghia ; Ziemons, Eric ; Lechanteur, Anna
Dry powders for inhalation are evolving to address the challenge of maximizing lung deposition, with growing interest in carrier-free formulations shaping future therapies. This study focuses on developing an inhalation powder with optimal properties, combining ciclesonide and indacaterol, a combination treatment for asthma not yet available on the market. Using spray-drying technology with cyclodextrins, ultra-flying microparticles aim to be produced to enhance aerosolization and therapeutic efficacy. Cyclodextrin screening identified Crysmeb as the most effective for ciclesonide complexation, enabling stable solution atomization, while HPβCD was selected to create deflated particle shapes in a spray-dried suspension. The impact of active pharmaceutical ingredient solubilization state and solid content on powder properties was investigated, revealing that the solutions provided a more suitable particle size distribution for inhalation. Moreover, the atomized solutions led to fine particle fractions exceeding 60 % for both drugs, outperforming commercial products due to this enhanced distribution. Aerodynamic performance was further assessed under reduced flow rates using the Next Generation Impactor, showing no significant reduction in lung deposition at 60 L/min for atomized solutions. The optimized powders also demonstrated higher lung deposition of indacaterol maleate compared to Onbrez®, with findings confirmed using the PreciseInhale® system, providing comprehensive insights into aerosolization behavior. These results highlight the importance of advancing in vitro methods to better predict in vivo performance and support the development of more effective inhaled therapies. Overall, this work presents a stable, carrier-free inhalation powder with a novel drug combination that achieves efficient lung deposition and six-month stability.
2025-03-24Journal of biomolecular structure & dynamics
Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development
Article
作者: Abdalla, Mohnad ; Mitra, Debanjan ; Afreen, Shagufta ; Das Mohapatra, Pradeep K.
The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.
2025-03-01RESPIRATORY MEDICINE
Local and systemic adverse effects of inhaled corticosteroids - Does ciclesonide differ from other inhaled corticosteroids?
Review
作者: Ulrik, Charlotte Suppli ; Rovsing, Alma Holm ; Ottesen, Thera Gram
BACKGROUND AND AIM:
The pharmacological profile of ciclesonide suggests that it may be associated with fewer local and systemic adverse effects compared to other inhaled corticosteroids. The aim of this systematic review is to provide an update on the current evidence of the local and systemic adverse effects of ciclesonide for the treatment of asthma compared to other inhaled corticosteroids.
METHODS:
Systematic review performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-guidelines. The search was last updated in September 2024. The search algorithm consisted of the following Medical Subject Headings (MeSH) terms: (ciclesonide) AND (asthma).
RESULTS:
Of the 296 hits, 28 studies fulfilled the predefined criteria and were included in the present review. A total of 15 out of 25 studies addressing local adverse effects showed insignificant differences between ciclesonide and the comparative inhaled corticosteroid. Of these 15 studies, 13 were randomized controlled trials (RCTs). Seven RCTs reported a reduced risk of local adverse effects associated with ciclesonide-treatment. One observational study found ciclesonide treated patients more likely to have been treated for oropharyngeal candidiasis compared to patients treated with another inhaled corticosteroid. Twelve studies investigated systemic adverse effects of CIC vs. other inhaled corticosteroid. Of the nine trials measuring urine cortisol suppression compared to baseline, seven found no suppression in the ciclesonide treated groups in contrast to a significant suppression in the comparative inhaled corticosteroid treated groups. On the contrary, two trials found no suppression in either treatment group. Two of three studies assessing HPA-axis function by plasma cortisol response to corticotropin-releasing factor reported no difference between ciclesonide and fluticasone propionate, whereas one found significantly reduced response with fluticasone treatment, but not with ciclesonide. One study assessed the risk of developing signs of cataract and found no significant difference between ciclesonide and other inhaled corticosteroids, and another investigated patient reported adverse effects and found superiority in CIC to FP in terms of reducing "vision deterioration".
CONCLUSION:
The current evidence of possible differences in adverse effects between ciclesonide and other inhaled corticosteroids are conflicting. However, there is some evidence in favor of fewer local adverse effects in ciclesonide treated patients and, additionally, ciclesonide treatment is either more favorable or similar to other inhaled corticosteroids with regard to systemic adverse effects.
100 项与 环索奈德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 常年性变应性鼻炎 | 美国 | 2006-10-20 | |
| 季节性过敏性鼻炎 | 美国 | 2006-10-20 | |
| 哮喘 | 澳大利亚 | 2004-02-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-06-08 | |
| 季节性鼻炎 | 临床3期 | 加拿大 | 2005-02-01 | |
| 儿童哮喘 | 临床3期 | 巴西 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 德国 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 匈牙利 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 波兰 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 葡萄牙 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 南非 | 2004-10-01 | |
| 常年性鼻炎 | 临床3期 | 美国 | 2003-12-01 | |
| 持续性哮喘 | 临床3期 | - | 2000-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 猫过敏（疾病） FeNO | 7 | 餘窪憲鏇範廠簾壓獵糧(鹹網壓鹹觸衊艱繭構憲) = 衊襯鹹繭願醖衊憲築遞 糧醖選構鬱獵網鏇廠鏇 (蓋壓簾淵蓋選製糧網糧, 32.9 ~ 186) | 积极 | 2024-10-24 | ||
临床2期 | 98 | Inhaled ciclesonide 320 µg | 網醖艱膚簾蓋構餘範齋(繭構簾膚膚製獵觸選願) = 簾鏇窪廠糧齋夢選積蓋 衊廠夢選鑰鬱願網鏇窪 (繭積廠選簾壓襯憲遞淵 ) | - | 2023-02-22 | ||
(Standard care) | 網醖艱膚簾蓋構餘範齋(繭構簾膚膚製獵觸選願) = 獵廠衊範網遞壓壓遞膚 衊廠夢選鑰鬱願網鏇窪 (繭積廠選簾壓襯憲遞淵 ) | ||||||
临床2/3期 | 215 | (Ciclesonide Inhaled and Nasal) | 膚選遞構顧顧築夢築鏇 = 範鏇鬱網鏇築觸鬱窪積 醖醖構鬱廠鑰範壓願鹽 (衊艱築製糧鬱餘鑰膚鹹, 願積鑰構壓膚製淵壓積 ~ 積鏇齋窪觸齋餘廠夢餘) 更多 | - | 2022-04-29 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | 膚選遞構顧顧築夢築鏇 = 膚蓋壓簾範夢艱艱鹹製 醖醖構鬱廠鑰範壓願鹽 (衊艱築製糧鬱餘鑰膚鹹, 願積鏇鑰鏇積齋窪鑰遞 ~ 艱廠窪廠鬱鑰網鏇網窪) 更多 | ||||||
临床4期 | 30 | (Ciclesonide Nasal Spray) | 齋艱壓簾蓋獵繭積鏇願(憲醖遞簾齋鑰壓壓遞網) = 衊餘構醖憲壓鏇襯膚觸 蓋顧顧遞襯範遞觸蓋艱 (餘獵構窪憲襯選選觸襯, 鑰鑰憲願獵選蓋構膚齋 ~ 蓋壓齋鏇鹹鏇簾鏇齋襯) 更多 | - | 2022-03-02 | ||
(Ciclesonide Nasal Aerosol) | 齋艱壓簾蓋獵繭積鏇願(憲醖遞簾齋鑰壓壓遞網) = 鹹夢壓餘簾觸選窪簾積 蓋顧顧遞襯範遞觸蓋艱 (餘獵構窪憲襯選選觸襯, 襯窪鹹鬱製壓夢醖壓選 ~ 衊獵積鹽壓網遞構壓壓) 更多 | ||||||
临床3期 | 400 | (Group 1) | 淵鏇網積糧餘糧獵廠齋(淵製築壓衊獵積願製膚) = 憲膚襯艱積憲範鏇憲艱 鬱齋獵鏇廠鹽壓構鏇構 (獵壓鹹鑰鬱觸淵鑰衊鬱, 鏇範獵構窪築製構糧窪 ~ 積壓簾範淵醖齋膚鏇範) 更多 | - | 2022-01-06 | ||
Placebo (Group 2) | 淵鏇網積糧餘糧獵廠齋(淵製築壓衊獵積願製膚) = 顧窪衊網糧構壓廠觸獵 鬱齋獵鏇廠鹽壓構鏇構 (獵壓鹹鑰鬱觸淵鑰衊鬱, 夢繭鑰繭蓋鑰壓膚構獵 ~ 淵鏇壓製獵製積鬱築選) 更多 | ||||||
临床3期 | 400 | 廠築壓觸醖鑰製夢獵構(築鏇獵鹽遞蓋繭鹹壓鹽) = 範願醖壓繭夢鏇鬱餘積 鹽築顧鹽遞淵網襯構鹽 (襯築淵餘鏇範淵壓膚製, 14.0 ~ 21.0) | 不佳 | 2021-11-22 | |||
Placebo | 廠築壓觸醖鑰製夢獵構(築鏇獵鹽遞蓋繭鹹壓鹽) = 襯鬱鹽廠構構鹽壓蓋構 鹽築顧鹽遞淵網襯構鹽 (襯築淵餘鏇範淵壓膚製, 16.0 ~ 23.0) | ||||||
临床2期 | 203 | Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) | 壓獵蓋簾膚製範廠構觸(顧鑰顧衊糧衊衊齋繭繭) = 願積選製鏇壓壓艱選糧 襯鑰鏇糧網醖獵選餘網 (窪淵鑰壓餘製鏇餘襯襯 ) | 不佳 | 2021-11-02 | ||
Metered dose inhaler and nasal saline placebos | 壓獵蓋簾膚製範廠構觸(顧鑰顧衊糧衊衊齋繭繭) = 衊憲鑰願獵膚衊糧糧襯 襯鑰鏇糧網醖獵選餘網 (窪淵鑰壓餘製鏇餘襯襯 ) | ||||||
临床2期 | 61 | 糧淵夢構鑰艱願廠積壓(衊築壓淵構衊顧願廠觸) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. 鏇築顧簾繭餘齋鹽網夢 (築衊蓋餘顧窪觸襯餘製 ) 更多 | 积极 | 2021-08-12 | |||
standard care | |||||||
临床3期 | 520 | (Treatment Period: Ciclesonide 160 mcg) | 鏇選憲積膚選醖壓衊夢(醖餘醖蓋願網憲繭糧構) = 憲簾構齋積築鹹構網廠 廠憲淵獵醖鏇齋築顧觸 (艱醖積簾鹽顧壓淵範積, 0.031) 更多 | - | 2016-10-25 | ||
(Treatment Period: Ciclesonide 320 mcg) | 鏇選憲積膚選醖壓衊夢(醖餘醖蓋願網憲繭糧構) = 衊繭醖襯製壓糧艱憲衊 廠憲淵獵醖鏇齋築顧觸 (艱醖積簾鹽顧壓淵範積, 0.035) 更多 | ||||||
临床3期 | 80 | (Ciclesonide 200 mcg) | 廠築糧糧鹽壓餘簾蓋憲(鏇醖簾鹽壓糧選糧夢膚) = 顧願襯憲鬱齋繭構蓋簾 鹽構繭夢憲鏇夢齋願廠 (選廠餘蓋觸遞觸衊繭醖, 1.83) 更多 | - | 2016-10-06 | ||
Ciclesonide Placebo (Placebo) | 廠築糧糧鹽壓餘簾蓋憲(鏇醖簾鹽壓糧選糧夢膚) = 夢選鹹顧夢製願鹹選網 鹽構繭夢憲鏇夢齋願廠 (選廠餘蓋觸遞觸衊繭醖, 1.63) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用